- Home
- ROIV vs ENSG Comparison
ROIV vs ENSG Comparison
Compare ROIV & ENSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- ENSG
- Stock Information
- Founded
- ROIV 2014
- ENSG 1999
- Country
- ROIV United Kingdom
- ENSG United States
- Employees
- ROIV N/A
- ENSG N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- ENSG Hospital/Nursing Management
- Sector
- ROIV Health Care
- ENSG Health Care
- Exchange
- ROIV Nasdaq
- ENSG Nasdaq
- Market Cap
- ROIV 8.4B
- ENSG 7.5B
- IPO Year
- ROIV N/A
- ENSG 2007
- Fundamental
- Price
- ROIV $10.38
- ENSG $128.74
- Analyst Decision
- ROIV Strong Buy
- ENSG Buy
- Analyst Count
- ROIV 6
- ENSG 7
- Target Price
- ROIV $17.10
- ENSG $166.14
- AVG Volume (30 Days)
- ROIV 7.0M
- ENSG 425.2K
- Earning Date
- ROIV 02-10-2025
- ENSG 04-30-2025
- Dividend Yield
- ROIV N/A
- ENSG 0.19%
- EPS Growth
- ROIV N/A
- ENSG 40.27
- EPS
- ROIV N/A
- ENSG 5.12
- Revenue
- ROIV $122,585,000.00
- ENSG $4,260,484,999.00
- Revenue This Year
- ROIV N/A
- ENSG $16.54
- Revenue Next Year
- ROIV N/A
- ENSG $9.51
- P/E Ratio
- ROIV N/A
- ENSG $25.14
- Revenue Growth
- ROIV 140.04
- ENSG 14.24
- 52 Week Low
- ROIV $9.96
- ENSG $113.27
- 52 Week High
- ROIV $13.06
- ENSG $158.45
- Technical
- Relative Strength Index (RSI)
- ROIV 42.16
- ENSG 47.00
- Support Level
- ROIV $10.63
- ENSG $127.26
- Resistance Level
- ROIV $11.42
- ENSG $132.00
- Average True Range (ATR)
- ROIV 0.36
- ENSG 2.78
- MACD
- ROIV -0.02
- ENSG 0.24
- Stochastic Oscillator
- ROIV 7.59
- ENSG 56.07
Stock Price Comparison Chart: ROIV vs ENSG
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.